ALS Phase II Study of NX210c

Clinical trial NCT06365216 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06365216
Sponsor: Axoltis Pharma
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Amyotrophic Lateral Sclerosis

Start date: 2024-10-25
Primary completion: 2026-02-01
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.